
    
      Subjects who provide voluntary written informed consent will be screened for eligibility.
      Subjects meeting all of the inclusion and none of the exclusion criteria will be eligible to
      participate.

      Subjects will be required to arrive at the hospital (or phase 1 unit if applicable) for
      dosing at least 2 hours before the planned surgical excision. Following dosing, subjects will
      be monitored for safety and surgical excision will occur at least 2 hours after study product
      administration.
    
  